Education
About Us
Working with TipRanks
Follow Us
Apellis Pharmaceuticals Inc (APLS)
NASDAQ:APLS
APLS Stock Chart & Stats
$20.33
-$1.37(-3.96%)
At close: 4:00 PM EST
$20.33
-$1.37(-3.96%)
Day’s Range― - ―
52-Week Range$16.10 - $35.72
Previous CloseN/A
Volume215.04K
Average Volume (3M)2.97M
Market Cap
$2.57B
Enterprise Value$2.94B
Total Cash (Recent Filing)$479.17M
Total Debt (Recent Filing)$114.28M
Price to Earnings (P/E)68.5
Beta0.88
Next Earnings
Mar 04, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.67
Shares Outstanding126,525,215
10 Day Avg. Volume2,957,917
30 Day Avg. Volume2,973,966
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)17.30
Price to Sales (P/S)5.06
P/FCF Ratio-44.79
Enterprise Value/Market Cap1.14
Enterprise Value/Revenue2.89
Enterprise Value/Gross Profit3.26
Enterprise Value/Ebitda31.47
Forecast
1Y Price Target
$33.07Price Target Upside62.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
EPS Forecast (FY)0.26
Revenue Forecast (FY)$1.01B
Bulls Say, Bears Say
Bulls Say
Efficacy Of TreatmentsThe analysis showed that patients treated with pegcetacoplan monthly experienced a 31% reduction in lesion growth, reinforcing the durable efficacy of Syfovre.
Market LeadershipSyfovre continues to maintain market leadership, accounting for ~52% of new patient starts and >60% of total GA market share.
Revenue PerformanceEmpaveli revenue was $26.8 million, beating consensus of $22.5 million, as the launch in C3G/IC-MPGN more than offset any decline in PNH.
Bears Say
Co-Pay Assistance IssuesOngoing co-pay issues are putting significant pressure on APLS shares.
Market FragmentationFragmented market and potential payor access issues could limit Empaveli uptake.
Revenue Growth ChallengesSyfovre revenue has been flattish, and the current launch is heading into a 'high-scatter' indication where patient-finding may be a challenge.
Apellis Pharmaceuticals News
APLS FAQ
What was Apellis Pharmaceuticals Inc’s price range in the past 12 months?
Apellis Pharmaceuticals Inc lowest stock price was $16.10 and its highest was $35.72 in the past 12 months.
What is Apellis Pharmaceuticals Inc’s market cap?
Apellis Pharmaceuticals Inc’s market cap is $2.57B.
When is Apellis Pharmaceuticals Inc’s upcoming earnings report date?
Apellis Pharmaceuticals Inc’s upcoming earnings report date is Mar 04, 2026 which is in 106 days.
How were Apellis Pharmaceuticals Inc’s earnings last quarter?
Apellis Pharmaceuticals Inc released its earnings results on Oct 30, 2025. The company reported $1.67 earnings per share for the quarter, beating the consensus estimate of $1.579 by $0.091.
Is Apellis Pharmaceuticals Inc overvalued?
According to Wall Street analysts Apellis Pharmaceuticals Inc’s price is currently Undervalued.
Does Apellis Pharmaceuticals Inc pay dividends?
Apellis Pharmaceuticals Inc does not currently pay dividends.
What is Apellis Pharmaceuticals Inc’s EPS estimate?
Apellis Pharmaceuticals Inc’s EPS estimate is -0.37.
How many shares outstanding does Apellis Pharmaceuticals Inc have?
Apellis Pharmaceuticals Inc has 126,525,215 shares outstanding.
What happened to Apellis Pharmaceuticals Inc’s price movement after its last earnings report?
Apellis Pharmaceuticals Inc reported an EPS of $1.67 in its last earnings report, beating expectations of $1.579. Following the earnings report the stock price went down -31.015%.
Which hedge fund is a major shareholder of Apellis Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in APLS
Apellis Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$33.07 (62.67% Upside)
$33.07 (62.67% Upside)
Blogger Sentiment
Bullish
APLS Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 336.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $7.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.2%
Last 30 Days ▲ 18.9%
Last 30 Days ▲ 18.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-27.54%
12-Months-Change
Fundamentals
Return on Equity
14.10%
Trailing 12-Months
Asset Growth
17.39%
Trailing 12-Months
Company Description
Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative therapies to treat serious diseases. The company specializes in complement immunotherapy, targeting the complement system to provide solutions for conditions such as geographic atrophy and other rare diseases. Apellis is primarily engaged in the research, development, and commercialization of its core product, pegcetacoplan, which is designed to address unmet medical needs in the ophthalmology and hematology sectors.
APLS Company Deck
APLS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected significant progress with the FDA approval of EMPAVELI and strong market leadership of SYFOVRE. However, challenges in SYFOVRE revenue due to free drug programs and operational challenges in patient access were notable concerns.View all APLS earnings summariesAPLS Stock 12 Month Forecast
Average Price Target
$33.07
▲(62.67% Upside)
Technical Analysis
Zai Lab
―
Crinetics Pharmaceuticals
―
Akero Therapeutics
―
Mirum Pharmaceuticals
―
MoonLake Immunotherapeutics
―
Ownership Overview
3.17% Insiders
18.42% Mutual Funds
41.80% Other Institutional Investors
22.27% Public Companies and Individual Investors